Outcomes of Upadacitinib following Dupilumab for Dupilumab-Associated Facial and Neck Erythema: A Systematic Review

Dupilumab, an anti-IL-13 and anti-IL-4 antibody, is a mainstay of treatment for moderate-to-severe atopic dermatitis. However, dupilumab-associated facial and/or neck erythema (DA-FNE) has been reported to be a relatively common adverse event. There have been increasing reports of upadacitinib as a potential treatment for DA-FNE. Here we systematically review the outcomes of patients who initiated upadacitinib after discontinuation from dupilumab for DA-FNE.

Dupilumab，作为一种针对IL-13和IL-4的抗体，是治疗中重度特应性皮炎的主要手段。然而，Dupilumab相关面部及/或颈部红斑（简称DA-FNE）已被报道为一种相对常见的不良事件。随着Upadacitinib作为DA-FNE潜在治疗方法的报道逐渐增多，本文将系统地回顾那些在停用Dupilumab后开始使用Upadacitinib治疗的患者所取得的疗效。